Testing Liposomal Annamycin for Soft Tissue Sarcomas with Lung Metastases

Phase 1b/2 Study of Liposomal Annamycin (L-Annamycin) in Subjects With Previously Treated Soft-Tissue Sarcomas (STS) With Pulmonary Metastases (ANNA-SARC)

This study is testing a new treatment called liposomal Annamycin to see if it can help people with soft tissue sarcomas that have spread to their lungs after other treatments have failed.

Quick facts

• Phase: Phase1; Phase2
• Study type: Interventional
• Enrollment: 64 (estimated)
• Ages: 18 Years and up
• Sex: All
• Sponsor: Maria Sklodowska-Curie National Research Institute of Oncology (Academic / other)
• Drugs / interventions: chemotherapy, doxorubicin
• Locations: 1 site (Warsaw, Mazovian)
• Trial ID: NCT05518526 on ClinicalTrials.gov

What this trial studies

This clinical trial is a multi-centre, open-label, single-arm study designed to evaluate the safety and efficacy of liposomal Annamycin (L-Annamycin) in patients with previously treated soft tissue sarcomas (STS) that have spread to the lungs. The study consists of a Phase 1b component to determine the maximum-tolerated dose (MTD) and a Phase 2 component to assess the drug's efficacy at the recommended dose. Participants will receive L-Annamycin weekly in 28-day cycles until disease progression or unacceptable toxicity occurs. The trial aims to provide a new treatment option for patients with advanced STS who have limited therapeutic alternatives.

Who should consider this trial

Good fit: Ideal candidates include adults aged 18 and older with a confirmed diagnosis of soft tissue sarcoma and measurable lung metastases who have previously received anthracycline therapy.

Not a fit: Patients with soft tissue sarcomas that are amenable to curative surgical resection or those who have not received prior anthracycline therapy may not benefit from this study.

Why it matters

Potential benefit: If successful, this treatment could offer a new therapeutic option for patients with advanced soft tissue sarcomas and pulmonary metastases.

How similar studies have performed: While the approach of using L-Annamycin is novel, similar studies with other anthracyclines have shown promise in treating soft tissue sarcomas.

Eligibility criteria

Inclusion Criteria:

1. The subject is ≥18 years old at the time of signing informed consent.
2. The subject has an ECOG performance status ≤2 with an estimated life expectancy of greater than three months.
3. The subject has a pathologically confirmed diagnosis of STS (including the following pathological subtypes: liposarcoma, leiomyosarcoma, synovial sarcoma, angiosarcoma, undifferentiated pleomorphic sarcoma, myxofibrosarcoma, malignant peripheral nerve sheath tumour, malignant solitary fibrous tumour, and pleomorphic RMS), and documented lung metastases that are considered eligible for chemotherapy and not eligible for potentially curative surgical resection.
4. The subject must have measurable disease in the lung, defined as, at a minimum, one lesion that can be accurately measured in at least one dimension of \>10 mm. Subjects with the extra-pulmonary disease are eligible.
5. The subject had prior anthracycline therapy (cumulative dose of ≤450 mg/m2) for their disease and has shown the progression of the disease before study entry - for phase II trial maximum of three previous lines of therapy (adjuvant/neoadjuvant regimen is counted as one line of systemic treatment)
6. At least two weeks must have passed following treatment for their disease with chemotherapy, investigational therapy, targeted agents, biological agents, immune modulators, and any toxicities must have resolved to ≤ grade 1 or previous baseline levels no more than four weeks after completing therapy (except alopecia and polyneuropathy).
7. The subject must have adequate laboratory results, including the following:

   1. Absolute neutrophil count ≥ 1500/mL and platelets ≥100,000/mL
   2. Hemoglobin ≥8.0 g/dL
   3. Adequate renal function (The Cockcroft-Gault equation will be used to estimate creatinine clearance. This equation is as follows: Creatinine clearance in milliliters per minute= \[140-age\] x body weight \[kg\]/72 x plasma creatinine \[mg/dL\]; multiplied by 0.85 for women. By using this equation, adequate renal function will be deemed to be a creatinine clearance of greater than 60 mL/minute)
   4. Bilirubin ≤1.5 x ULN (unless due to Gilbert's syndrome)
   5. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 × ULN (≤ 5 x ULN in subjects with liver metastases)
8. The subject is able to understand and sign the informed consent document, can communicate with the Investigator, and can understand and comply with the requirements of the protocol.
9. Vaccinated with a live vaccine within 28 days prior to the first dose of the study drug. COVID-19 vaccination with mRNA or replication incompetent viral vector vaccines and annual inactivated influenza vaccines are permitted.
10. All subjects (men and women) agree to practise effective contraception during the entire study period and after discontinuing the study drug unless documentation of infertility exists.

    1. Sexually active, fertile women must use two effective forms of contraception (abstinence, intrauterine device, oral contraceptive, or double barrier device) from the time of informed consent and until at least six months after discontinuing the study drug.
    2. Sexually active men and their sexual partners must use effective contraceptive methods from the time of informed consent until at least six months after discontinuing the study drug.

Exclusion Criteria:

1. The subject has any condition that, in the opinion of the Investigator, places the subject at unacceptable risk if they were to participate in the study.
2. Metastases to the central nervous system
3. The subject has left ventricular ejection fraction (LVEF) \<50%, valvular heart disease, or severe hypertension not controlled by medical therapy. Cardiac subjects with a New York Heart Association classification of 3 or 4 will be excluded, as will those with recent (≤ 6 months) myocardial infarction, unstable angina, or symptomatic congestive heart failure. The subject has a baseline QT/QTc interval \>480 msec, a history of additional risk factors for torsade des pointes (e.g., heart failure, hypokalemia, family history of Long QT Syndrome) and use of concomitant medications that significantly prolong the QT/QTc interval.
4. The subject has clinically relevant serious comorbid medical conditions including, but not limited to active infection, known positive status for human immunodeficiency virus and/or active hepatitis B or C, cirrhosis, or psychiatric illness/social situations that would limit compliance with study requirements.
5. The subject is pregnant, lactating, or not using adequate contraception.
6. The subject has a known allergy to study drug or excipients.
7. The subject is required to use moderate or strong inhibitors and inducers of cytochrome P450 (CYP) family enzymes CYP3A and CYP2B and transporters that cannot be held three days before treatment and on the day of treatment.

Where this trial is running

Warsaw, Mazovian

• Maria Sklodowska-Curie National Research Institute of Oncology — Warsaw, Mazovian, Poland (Recruiting)

Study contacts

• Study coordinator: Piotr Rutkowski, MD PhD Professor

Conditions Soft Tissue Sarcoma; Pulmonary Metastasis